nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2C—Sorafenib—thyroid cancer	0.212	0.4	CbGbCtD
Atomoxetine—CYP2C19—Sorafenib—thyroid cancer	0.0836	0.158	CbGbCtD
Atomoxetine—CYP3A4—Vandetanib—thyroid cancer	0.0671	0.127	CbGbCtD
Atomoxetine—CYP2D6—Sorafenib—thyroid cancer	0.0636	0.12	CbGbCtD
Atomoxetine—CYP3A4—Sorafenib—thyroid cancer	0.0404	0.0763	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—thyroid cancer	0.0386	0.0728	CbGbCtD
Atomoxetine—CYP3A4—Doxorubicin—thyroid cancer	0.0245	0.0463	CbGbCtD
Atomoxetine—Pelvic pain—Epirubicin—thyroid cancer	0.0023	0.00602	CcSEcCtD
Atomoxetine—Tremor—Vandetanib—thyroid cancer	0.0023	0.00602	CcSEcCtD
Atomoxetine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00228	0.00596	CcSEcCtD
Atomoxetine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00219	0.00572	CcSEcCtD
Atomoxetine—Loss of consciousness—Vandetanib—thyroid cancer	0.00216	0.00564	CcSEcCtD
Atomoxetine—Weight decreased—Sorafenib—thyroid cancer	0.00215	0.00562	CcSEcCtD
Atomoxetine—Cough—Vandetanib—thyroid cancer	0.00214	0.0056	CcSEcCtD
Atomoxetine—Pelvic pain—Doxorubicin—thyroid cancer	0.00213	0.00557	CcSEcCtD
Atomoxetine—Convulsion—Vandetanib—thyroid cancer	0.00213	0.00556	CcSEcCtD
Atomoxetine—Infestation NOS—Sorafenib—thyroid cancer	0.00212	0.00554	CcSEcCtD
Atomoxetine—Infestation—Sorafenib—thyroid cancer	0.00212	0.00554	CcSEcCtD
Atomoxetine—Arthralgia—Vandetanib—thyroid cancer	0.00209	0.00547	CcSEcCtD
Atomoxetine—Chest pain—Vandetanib—thyroid cancer	0.00209	0.00547	CcSEcCtD
Atomoxetine—Anxiety—Vandetanib—thyroid cancer	0.00208	0.00545	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00207	0.00543	CcSEcCtD
Atomoxetine—Dry mouth—Vandetanib—thyroid cancer	0.00204	0.00535	CcSEcCtD
Atomoxetine—Infection—Vandetanib—thyroid cancer	0.00199	0.00521	CcSEcCtD
Atomoxetine—Nervous system disorder—Vandetanib—thyroid cancer	0.00196	0.00514	CcSEcCtD
Atomoxetine—Skin disorder—Vandetanib—thyroid cancer	0.00194	0.00509	CcSEcCtD
Atomoxetine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00188	0.00491	CcSEcCtD
Atomoxetine—Urethral disorder—Sorafenib—thyroid cancer	0.00186	0.00488	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00182	0.00477	CcSEcCtD
Atomoxetine—Insomnia—Vandetanib—thyroid cancer	0.00181	0.00474	CcSEcCtD
Atomoxetine—Paraesthesia—Vandetanib—thyroid cancer	0.0018	0.00471	CcSEcCtD
Atomoxetine—Cardiac disorder—Sorafenib—thyroid cancer	0.00176	0.00462	CcSEcCtD
Atomoxetine—Flushing—Sorafenib—thyroid cancer	0.00176	0.00462	CcSEcCtD
Atomoxetine—Dyspepsia—Vandetanib—thyroid cancer	0.00176	0.00461	CcSEcCtD
Atomoxetine—Decreased appetite—Vandetanib—thyroid cancer	0.00174	0.00455	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00173	0.00452	CcSEcCtD
Atomoxetine—Fatigue—Vandetanib—thyroid cancer	0.00173	0.00452	CcSEcCtD
Atomoxetine—Angiopathy—Sorafenib—thyroid cancer	0.00172	0.00451	CcSEcCtD
Atomoxetine—Rigors—Epirubicin—thyroid cancer	0.00171	0.00448	CcSEcCtD
Atomoxetine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00171	0.00448	CcSEcCtD
Atomoxetine—Constipation—Vandetanib—thyroid cancer	0.00171	0.00448	CcSEcCtD
Atomoxetine—Pain—Vandetanib—thyroid cancer	0.00171	0.00448	CcSEcCtD
Atomoxetine—Mental disorder—Sorafenib—thyroid cancer	0.00167	0.00436	CcSEcCtD
Atomoxetine—Malnutrition—Sorafenib—thyroid cancer	0.00165	0.00433	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00164	0.00428	CcSEcCtD
Atomoxetine—Delirium—Epirubicin—thyroid cancer	0.00163	0.00426	CcSEcCtD
Atomoxetine—Dysgeusia—Sorafenib—thyroid cancer	0.00162	0.00424	CcSEcCtD
Atomoxetine—Muscle spasms—Sorafenib—thyroid cancer	0.00159	0.00416	CcSEcCtD
Atomoxetine—Rigors—Doxorubicin—thyroid cancer	0.00159	0.00415	CcSEcCtD
Atomoxetine—Abdominal pain—Vandetanib—thyroid cancer	0.00158	0.00414	CcSEcCtD
Atomoxetine—Body temperature increased—Vandetanib—thyroid cancer	0.00158	0.00414	CcSEcCtD
Atomoxetine—Bone disorder—Epirubicin—thyroid cancer	0.00155	0.00405	CcSEcCtD
Atomoxetine—Delirium—Doxorubicin—thyroid cancer	0.0015	0.00394	CcSEcCtD
Atomoxetine—Syncope—Sorafenib—thyroid cancer	0.00148	0.00388	CcSEcCtD
Atomoxetine—Loss of consciousness—Sorafenib—thyroid cancer	0.00145	0.00381	CcSEcCtD
Atomoxetine—Cough—Sorafenib—thyroid cancer	0.00144	0.00378	CcSEcCtD
Atomoxetine—Asthenia—Vandetanib—thyroid cancer	0.00144	0.00376	CcSEcCtD
Atomoxetine—Bone disorder—Doxorubicin—thyroid cancer	0.00143	0.00375	CcSEcCtD
Atomoxetine—Pruritus—Vandetanib—thyroid cancer	0.00142	0.00371	CcSEcCtD
Atomoxetine—Myalgia—Sorafenib—thyroid cancer	0.00141	0.00369	CcSEcCtD
Atomoxetine—Arthralgia—Sorafenib—thyroid cancer	0.00141	0.00369	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0014	0.00366	CcSEcCtD
Atomoxetine—Abnormal dreams—Epirubicin—thyroid cancer	0.00138	0.00362	CcSEcCtD
Atomoxetine—Dry mouth—Sorafenib—thyroid cancer	0.00138	0.00361	CcSEcCtD
Atomoxetine—Diarrhoea—Vandetanib—thyroid cancer	0.00137	0.00359	CcSEcCtD
Atomoxetine—Infection—Sorafenib—thyroid cancer	0.00134	0.00351	CcSEcCtD
Atomoxetine—Shock—Sorafenib—thyroid cancer	0.00133	0.00348	CcSEcCtD
Atomoxetine—Nervous system disorder—Sorafenib—thyroid cancer	0.00132	0.00347	CcSEcCtD
Atomoxetine—Dizziness—Vandetanib—thyroid cancer	0.00132	0.00347	CcSEcCtD
Atomoxetine—Skin disorder—Sorafenib—thyroid cancer	0.00131	0.00343	CcSEcCtD
Atomoxetine—Anorexia—Sorafenib—thyroid cancer	0.00129	0.00337	CcSEcCtD
Atomoxetine—Abnormal dreams—Doxorubicin—thyroid cancer	0.00128	0.00335	CcSEcCtD
Atomoxetine—Coma—Epirubicin—thyroid cancer	0.00128	0.00335	CcSEcCtD
Atomoxetine—Vomiting—Vandetanib—thyroid cancer	0.00127	0.00333	CcSEcCtD
Atomoxetine—Rash—Vandetanib—thyroid cancer	0.00126	0.0033	CcSEcCtD
Atomoxetine—Dermatitis—Vandetanib—thyroid cancer	0.00126	0.0033	CcSEcCtD
Atomoxetine—Headache—Vandetanib—thyroid cancer	0.00125	0.00328	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00123	0.00322	CcSEcCtD
Atomoxetine—Nausea—Vandetanib—thyroid cancer	0.00119	0.00311	CcSEcCtD
Atomoxetine—Dyspepsia—Sorafenib—thyroid cancer	0.00119	0.00311	CcSEcCtD
Atomoxetine—Coma—Doxorubicin—thyroid cancer	0.00118	0.0031	CcSEcCtD
Atomoxetine—Decreased appetite—Sorafenib—thyroid cancer	0.00117	0.00307	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00117	0.00305	CcSEcCtD
Atomoxetine—Fatigue—Sorafenib—thyroid cancer	0.00116	0.00305	CcSEcCtD
Atomoxetine—Pain—Sorafenib—thyroid cancer	0.00115	0.00302	CcSEcCtD
Atomoxetine—Constipation—Sorafenib—thyroid cancer	0.00115	0.00302	CcSEcCtD
Atomoxetine—Hepatic failure—Epirubicin—thyroid cancer	0.00113	0.00296	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0011	0.00289	CcSEcCtD
Atomoxetine—Hot flush—Epirubicin—thyroid cancer	0.00109	0.00284	CcSEcCtD
Atomoxetine—Menopausal symptoms—Epirubicin—thyroid cancer	0.00108	0.00282	CcSEcCtD
Atomoxetine—Urticaria—Sorafenib—thyroid cancer	0.00107	0.00281	CcSEcCtD
Atomoxetine—Body temperature increased—Sorafenib—thyroid cancer	0.00107	0.00279	CcSEcCtD
Atomoxetine—Abdominal pain—Sorafenib—thyroid cancer	0.00107	0.00279	CcSEcCtD
Atomoxetine—Hepatic failure—Doxorubicin—thyroid cancer	0.00105	0.00274	CcSEcCtD
Atomoxetine—Lethargy—Epirubicin—thyroid cancer	0.00104	0.00271	CcSEcCtD
Atomoxetine—Hot flush—Doxorubicin—thyroid cancer	0.001	0.00263	CcSEcCtD
Atomoxetine—Affect lability—Epirubicin—thyroid cancer	0.000999	0.00262	CcSEcCtD
Atomoxetine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000996	0.00261	CcSEcCtD
Atomoxetine—Asthenia—Sorafenib—thyroid cancer	0.000969	0.00254	CcSEcCtD
Atomoxetine—Mood swings—Epirubicin—thyroid cancer	0.000962	0.00252	CcSEcCtD
Atomoxetine—Lethargy—Doxorubicin—thyroid cancer	0.000959	0.00251	CcSEcCtD
Atomoxetine—Pruritus—Sorafenib—thyroid cancer	0.000955	0.0025	CcSEcCtD
Atomoxetine—Abdominal pain upper—Epirubicin—thyroid cancer	0.000927	0.00243	CcSEcCtD
Atomoxetine—Affect lability—Doxorubicin—thyroid cancer	0.000925	0.00242	CcSEcCtD
Atomoxetine—Diarrhoea—Sorafenib—thyroid cancer	0.000924	0.00242	CcSEcCtD
Atomoxetine—Breast disorder—Epirubicin—thyroid cancer	0.000918	0.0024	CcSEcCtD
Atomoxetine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000908	0.00238	CcSEcCtD
Atomoxetine—Dizziness—Sorafenib—thyroid cancer	0.000893	0.00234	CcSEcCtD
Atomoxetine—Mood swings—Doxorubicin—thyroid cancer	0.00089	0.00233	CcSEcCtD
Atomoxetine—Influenza—Epirubicin—thyroid cancer	0.000878	0.0023	CcSEcCtD
Atomoxetine—Vomiting—Sorafenib—thyroid cancer	0.000859	0.00225	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000858	0.00225	CcSEcCtD
Atomoxetine—Rash—Sorafenib—thyroid cancer	0.000851	0.00223	CcSEcCtD
Atomoxetine—Dermatitis—Sorafenib—thyroid cancer	0.000851	0.00223	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—thyroid cancer	0.000849	0.00222	CcSEcCtD
Atomoxetine—Headache—Sorafenib—thyroid cancer	0.000846	0.00221	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00084	0.0022	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—thyroid cancer	0.000821	0.00215	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000816	0.00213	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—thyroid cancer	0.000812	0.00213	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—thyroid cancer	0.000811	0.00212	CcSEcCtD
Atomoxetine—Nausea—Sorafenib—thyroid cancer	0.000802	0.0021	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—thyroid cancer	0.000794	0.00208	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—thyroid cancer	0.000783	0.00205	CcSEcCtD
Atomoxetine—Infestation NOS—Epirubicin—thyroid cancer	0.000783	0.00205	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—thyroid cancer	0.000761	0.00199	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—thyroid cancer	0.000759	0.00199	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000755	0.00198	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—thyroid cancer	0.00075	0.00196	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—thyroid cancer	0.000735	0.00192	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—thyroid cancer	0.000734	0.00192	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—thyroid cancer	0.000724	0.0019	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—thyroid cancer	0.000724	0.0019	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000704	0.00184	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000699	0.00183	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000694	0.00182	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—thyroid cancer	0.000689	0.0018	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—thyroid cancer	0.000679	0.00178	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—thyroid cancer	0.000652	0.00171	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—thyroid cancer	0.000652	0.00171	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000647	0.00169	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000642	0.00168	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—thyroid cancer	0.000637	0.00167	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—thyroid cancer	0.000637	0.00167	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000633	0.00166	CcSEcCtD
Atomoxetine—Chills—Epirubicin—thyroid cancer	0.00063	0.00165	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—thyroid cancer	0.000615	0.00161	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—thyroid cancer	0.000612	0.0016	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—thyroid cancer	0.000603	0.00158	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000603	0.00158	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—thyroid cancer	0.000603	0.00158	CcSEcCtD
Atomoxetine—Tension—Epirubicin—thyroid cancer	0.0006	0.00157	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—thyroid cancer	0.000599	0.00157	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—thyroid cancer	0.000594	0.00155	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—thyroid cancer	0.000592	0.00155	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—thyroid cancer	0.00059	0.00154	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—thyroid cancer	0.000588	0.00154	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000586	0.00153	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—thyroid cancer	0.000583	0.00153	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—thyroid cancer	0.000576	0.00151	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—thyroid cancer	0.000569	0.00149	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—thyroid cancer	0.000566	0.00148	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—thyroid cancer	0.000562	0.00147	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—thyroid cancer	0.000558	0.00146	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—thyroid cancer	0.000555	0.00145	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—thyroid cancer	0.000554	0.00145	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—thyroid cancer	0.00055	0.00144	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—thyroid cancer	0.000549	0.00144	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—thyroid cancer	0.000548	0.00144	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—thyroid cancer	0.000547	0.00143	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—thyroid cancer	0.000544	0.00142	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—thyroid cancer	0.00054	0.00141	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—thyroid cancer	0.000537	0.00141	CcSEcCtD
Atomoxetine—Cough—Epirubicin—thyroid cancer	0.000534	0.0014	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—thyroid cancer	0.000533	0.0014	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—thyroid cancer	0.00053	0.00139	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—thyroid cancer	0.000521	0.00136	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—thyroid cancer	0.000521	0.00136	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—thyroid cancer	0.000521	0.00136	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—thyroid cancer	0.00052	0.00136	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—thyroid cancer	0.000519	0.00136	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000517	0.00135	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—thyroid cancer	0.000509	0.00133	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—thyroid cancer	0.000508	0.00133	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—thyroid cancer	0.000507	0.00133	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—thyroid cancer	0.0005	0.00131	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000497	0.0013	CcSEcCtD
Atomoxetine—Infection—Epirubicin—thyroid cancer	0.000496	0.0013	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—thyroid cancer	0.000494	0.00129	CcSEcCtD
Atomoxetine—Shock—Epirubicin—thyroid cancer	0.000491	0.00129	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—thyroid cancer	0.00049	0.00128	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—thyroid cancer	0.000489	0.00128	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—thyroid cancer	0.000487	0.00127	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—thyroid cancer	0.000485	0.00127	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000482	0.00126	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—thyroid cancer	0.000482	0.00126	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—thyroid cancer	0.000482	0.00126	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—thyroid cancer	0.000482	0.00126	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—thyroid cancer	0.00048	0.00126	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000478	0.00125	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—thyroid cancer	0.000476	0.00125	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—thyroid cancer	0.000471	0.00123	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—thyroid cancer	0.000459	0.0012	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000455	0.00119	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—thyroid cancer	0.000454	0.00119	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000453	0.00119	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—thyroid cancer	0.000451	0.00118	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—thyroid cancer	0.000451	0.00118	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—thyroid cancer	0.000449	0.00117	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—thyroid cancer	0.000448	0.00117	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000446	0.00117	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—thyroid cancer	0.000444	0.00116	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—thyroid cancer	0.00044	0.00115	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—thyroid cancer	0.000439	0.00115	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—thyroid cancer	0.000434	0.00114	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000431	0.00113	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—thyroid cancer	0.00043	0.00113	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—thyroid cancer	0.000427	0.00112	CcSEcCtD
Atomoxetine—Pain—Epirubicin—thyroid cancer	0.000427	0.00112	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000421	0.0011	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—thyroid cancer	0.000418	0.00109	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—thyroid cancer	0.000415	0.00109	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—thyroid cancer	0.000411	0.00108	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—thyroid cancer	0.000411	0.00107	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000408	0.00107	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—thyroid cancer	0.000406	0.00106	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—thyroid cancer	0.000401	0.00105	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000399	0.00104	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—thyroid cancer	0.000398	0.00104	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—thyroid cancer	0.000396	0.00104	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—thyroid cancer	0.000395	0.00103	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—thyroid cancer	0.000395	0.00103	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—thyroid cancer	0.000395	0.00103	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—thyroid cancer	0.000395	0.00103	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000381	0.000996	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000378	0.000988	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—thyroid cancer	0.000367	0.00096	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—thyroid cancer	0.000365	0.000955	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—thyroid cancer	0.000365	0.000955	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—thyroid cancer	0.000358	0.000937	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—thyroid cancer	0.000353	0.000924	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—thyroid cancer	0.000341	0.000894	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—thyroid cancer	0.000331	0.000867	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—thyroid cancer	0.00033	0.000864	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—thyroid cancer	0.000327	0.000855	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—thyroid cancer	0.000317	0.000831	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—thyroid cancer	0.000316	0.000827	CcSEcCtD
Atomoxetine—Rash—Epirubicin—thyroid cancer	0.000315	0.000824	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—thyroid cancer	0.000314	0.000823	CcSEcCtD
Atomoxetine—Headache—Epirubicin—thyroid cancer	0.000313	0.000818	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—thyroid cancer	0.000305	0.000799	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—thyroid cancer	0.000296	0.000776	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—thyroid cancer	0.000294	0.000769	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—thyroid cancer	0.000291	0.000762	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—thyroid cancer	0.000291	0.000761	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—thyroid cancer	0.000289	0.000757	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—thyroid cancer	0.000274	0.000718	CcSEcCtD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000169	0.00192	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—SST—thyroid cancer	0.000166	0.00188	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TSHR—thyroid cancer	0.000164	0.00186	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TSHR—thyroid cancer	0.000162	0.00184	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDK1—thyroid cancer	0.000161	0.00183	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CALCA—thyroid cancer	0.00016	0.00181	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.000159	0.00181	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TSHR—thyroid cancer	0.000159	0.00181	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTCH1—thyroid cancer	0.000157	0.00179	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—PTEN—thyroid cancer	0.000157	0.00178	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000153	0.00174	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TSHR—thyroid cancer	0.000149	0.00169	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TSHR—thyroid cancer	0.000147	0.00167	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000146	0.00166	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000146	0.00166	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000145	0.00165	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TSHR—thyroid cancer	0.000144	0.00164	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—SST—thyroid cancer	0.000144	0.00163	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000142	0.00161	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CALCB—thyroid cancer	0.00014	0.00159	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CALCA—thyroid cancer	0.000139	0.00157	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000136	0.00154	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TRIM33—thyroid cancer	0.000132	0.0015	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—BRAF—thyroid cancer	0.00013	0.00148	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NRG1—thyroid cancer	0.000129	0.00147	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000129	0.00146	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—SST—thyroid cancer	0.000127	0.00144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTCH1—thyroid cancer	0.000126	0.00143	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—SST—thyroid cancer	0.000126	0.00143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTCH1—thyroid cancer	0.000125	0.00142	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—SST—thyroid cancer	0.000124	0.0014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTCH1—thyroid cancer	0.000123	0.00139	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CALCA—thyroid cancer	0.000122	0.00139	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CALCA—thyroid cancer	0.000121	0.00138	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CALCB—thyroid cancer	0.000121	0.00138	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TSHR—thyroid cancer	0.00012	0.00137	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TCF7L1—thyroid cancer	0.00012	0.00136	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CALCA—thyroid cancer	0.000119	0.00135	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TCF7L1—thyroid cancer	0.000119	0.00135	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MINPP1—thyroid cancer	0.000117	0.00133	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TCF7L1—thyroid cancer	0.000116	0.00132	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TERT—thyroid cancer	0.000116	0.00132	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SST—thyroid cancer	0.000115	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TRIM33—thyroid cancer	0.000115	0.0013	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SST—thyroid cancer	0.000115	0.0013	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000114	0.0013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SST—thyroid cancer	0.000112	0.00127	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CALCA—thyroid cancer	0.000111	0.00126	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HIF1A—thyroid cancer	0.000111	0.00126	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CALCA—thyroid cancer	0.00011	0.00125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TSHR—thyroid cancer	0.000109	0.00124	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CALCA—thyroid cancer	0.000108	0.00123	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000108	0.00122	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000107	0.00122	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—thyroid cancer	0.000107	0.00122	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TSHR—thyroid cancer	0.000105	0.00119	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CDK1—thyroid cancer	0.000101	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CDK1—thyroid cancer	9.99e-05	0.00113	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NDUFA13—thyroid cancer	9.93e-05	0.00113	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—NRAS—thyroid cancer	9.78e-05	0.00111	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CDK1—thyroid cancer	9.78e-05	0.00111	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	9.56e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TSHR—thyroid cancer	9.5e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—SST—thyroid cancer	9.37e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PRKAR1A—thyroid cancer	9.34e-05	0.00106	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CHST14—thyroid cancer	9.34e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTCH1—thyroid cancer	9.3e-05	0.00106	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BRAF—thyroid cancer	9.2e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	9.19e-05	0.00104	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	9.14e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CALCA—thyroid cancer	9.01e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TCF7L1—thyroid cancer	8.83e-05	0.001	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSHR—thyroid cancer	8.77e-05	0.000997	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSHR—thyroid cancer	8.71e-05	0.000989	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	8.63e-05	0.00098	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CHST14—thyroid cancer	8.59e-05	0.000976	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRKAR1A—thyroid cancer	8.56e-05	0.000973	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSHR—thyroid cancer	8.52e-05	0.000968	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SST—thyroid cancer	8.5e-05	0.000966	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—KRAS—thyroid cancer	8.42e-05	0.000957	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRKAR1A—thyroid cancer	8.39e-05	0.000953	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MEN1—thyroid cancer	8.25e-05	0.000937	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CALCA—thyroid cancer	8.19e-05	0.00093	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MEN1—thyroid cancer	8.19e-05	0.00093	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—SST—thyroid cancer	8.13e-05	0.000924	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	8.07e-05	0.000917	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MEN1—thyroid cancer	8.01e-05	0.00091	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	7.98e-05	0.000906	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	7.91e-05	0.000898	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	7.83e-05	0.000889	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	7.83e-05	0.000889	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	7.66e-05	0.000871	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HPGD—thyroid cancer	7.53e-05	0.000855	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTCH1—thyroid cancer	7.46e-05	0.000847	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CDK1—thyroid cancer	7.41e-05	0.000842	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTCH1—thyroid cancer	7.4e-05	0.000841	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SST—thyroid cancer	7.39e-05	0.000839	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTCH1—thyroid cancer	7.25e-05	0.000823	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HRAS—thyroid cancer	7.16e-05	0.000813	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	7.11e-05	0.000808	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MINPP1—thyroid cancer	7.03e-05	0.000798	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AKT1—thyroid cancer	6.96e-05	0.000791	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HPGD—thyroid cancer	6.92e-05	0.000787	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.87e-05	0.00078	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SST—thyroid cancer	6.82e-05	0.000775	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SST—thyroid cancer	6.77e-05	0.000769	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	6.72e-05	0.000763	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCND1—thyroid cancer	6.71e-05	0.000763	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SST—thyroid cancer	6.63e-05	0.000753	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CALCA—thyroid cancer	6.57e-05	0.000746	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CALCA—thyroid cancer	6.52e-05	0.00074	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTEN—thyroid cancer	6.48e-05	0.000736	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSHR—thyroid cancer	6.46e-05	0.000734	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	6.43e-05	0.000731	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CALCA—thyroid cancer	6.38e-05	0.000725	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKAR1A—thyroid cancer	6.36e-05	0.000722	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AKT1—thyroid cancer	6.32e-05	0.000718	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.11e-05	0.000694	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MEN1—thyroid cancer	6.07e-05	0.00069	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—HRAS—thyroid cancer	6e-05	0.000681	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	5.97e-05	0.000679	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDK1—thyroid cancer	5.94e-05	0.000675	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDK1—thyroid cancer	5.9e-05	0.00067	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.84e-05	0.000663	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NRAS—thyroid cancer	5.78e-05	0.000657	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDK1—thyroid cancer	5.78e-05	0.000656	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CHST14—thyroid cancer	5.62e-05	0.000638	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSHR—thyroid cancer	5.61e-05	0.000637	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	5.52e-05	0.000627	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTCH1—thyroid cancer	5.49e-05	0.000624	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MEN1—thyroid cancer	5.27e-05	0.000599	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SST—thyroid cancer	5.02e-05	0.000571	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—KRAS—thyroid cancer	4.97e-05	0.000565	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CALCA—thyroid cancer	4.84e-05	0.000549	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRG1—thyroid cancer	4.77e-05	0.000542	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	4.77e-05	0.000542	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRG1—thyroid cancer	4.74e-05	0.000538	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRG1—thyroid cancer	4.64e-05	0.000527	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HPGD—thyroid cancer	4.53e-05	0.000514	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—thyroid cancer	4.42e-05	0.000502	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDK1—thyroid cancer	4.38e-05	0.000497	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SST—thyroid cancer	4.36e-05	0.000496	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPR—thyroid cancer	4.32e-05	0.000491	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TERT—thyroid cancer	4.28e-05	0.000487	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	4.25e-05	0.000483	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TERT—thyroid cancer	4.25e-05	0.000483	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—thyroid cancer	4.23e-05	0.00048	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CALCA—thyroid cancer	4.2e-05	0.000477	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TERT—thyroid cancer	4.16e-05	0.000473	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HIF1A—thyroid cancer	4.1e-05	0.000465	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HIF1A—thyroid cancer	4.07e-05	0.000462	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	3.98e-05	0.000452	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPR—thyroid cancer	3.98e-05	0.000452	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.91e-05	0.000444	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.86e-05	0.000438	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDK1—thyroid cancer	3.8e-05	0.000432	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—thyroid cancer	3.73e-05	0.000424	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—NRAS—thyroid cancer	3.61e-05	0.00041	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—NRAS—thyroid cancer	3.58e-05	0.000407	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRG1—thyroid cancer	3.51e-05	0.000399	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	3.51e-05	0.000398	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—thyroid cancer	3.39e-05	0.000385	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—thyroid cancer	3.37e-05	0.000382	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—thyroid cancer	3.3e-05	0.000375	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A5—thyroid cancer	3.24e-05	0.000368	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—thyroid cancer	3.15e-05	0.000358	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—thyroid cancer	3.11e-05	0.000353	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—thyroid cancer	3.08e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRG1—thyroid cancer	3.05e-05	0.000347	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.03e-05	0.000345	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	3.02e-05	0.000343	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	3.02e-05	0.000343	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.98e-05	0.000338	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—thyroid cancer	2.74e-05	0.000311	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RXRA—thyroid cancer	2.72e-05	0.000309	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.66e-05	0.000302	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.65e-05	0.000301	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.64e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	2.62e-05	0.000298	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.62e-05	0.000298	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPR—thyroid cancer	2.6e-05	0.000295	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.57e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	2.57e-05	0.000291	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.56e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	2.55e-05	0.000289	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RXRA—thyroid cancer	2.5e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.5e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	2.49e-05	0.000283	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.48e-05	0.000281	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—thyroid cancer	2.46e-05	0.000279	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—thyroid cancer	2.41e-05	0.000273	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.39e-05	0.000271	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—thyroid cancer	2.37e-05	0.000269	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.33e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—thyroid cancer	2.32e-05	0.000264	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	2.31e-05	0.000263	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.31e-05	0.000262	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	2.29e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	2.27e-05	0.000257	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	2.17e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—thyroid cancer	2.13e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—thyroid cancer	2.12e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—thyroid cancer	2.07e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.99e-05	0.000226	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.95e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.94e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.89e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.84e-05	0.000208	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.82e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.82e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.78e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.76e-05	0.0002	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—thyroid cancer	1.72e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.72e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.69e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.64e-05	0.000187	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RXRA—thyroid cancer	1.64e-05	0.000186	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—thyroid cancer	1.63e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.62e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.58e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.58e-05	0.00018	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.58e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.57e-05	0.000178	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.56e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—thyroid cancer	1.55e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.53e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.52e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.49e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.38e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—thyroid cancer	1.37e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.36e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.35e-05	0.000154	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—thyroid cancer	1.35e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—thyroid cancer	1.34e-05	0.000152	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.24e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.2e-05	0.000136	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—thyroid cancer	1.18e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.17e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1.15e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—thyroid cancer	1.08e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—thyroid cancer	1.04e-05	0.000118	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—thyroid cancer	1.03e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	1.01e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	9.98e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	8.81e-06	0.0001	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—thyroid cancer	8.12e-06	9.23e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—thyroid cancer	7.08e-06	8.05e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—thyroid cancer	6.79e-06	7.71e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—thyroid cancer	6.24e-06	7.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—thyroid cancer	4.08e-06	4.64e-05	CbGpPWpGaD
